

### AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of inhibiting tumor growth in a subject suffering from neoplastic disease comprising:  
identifying a subject suffering from neoplastic disease;  
administering to said subject an effective NK cell activating amount of an NK cell activating cytokine selected from the group consisting of IL-1, IL-12, IFN- $\beta$ , and IFN- $\gamma$  or an NK cell activating flavonoid selected from the group consisting of flavone-8-acetic acid (FAA), xanthone-4-acetic acid, analogs of FAA, and methyl-substituted derivatives of FAA ~~wherein said NK cell activating cytokine is not IL-2 or IFN- $\alpha$ ; and~~  
administering a compound effective to inhibit the production or release of hydrogen peroxide selected from the group consisting of histamine, other H<sub>2</sub> receptor agonists, and serotonin.
2. (Original) The method of Claim 1, wherein the administration of said NK cell activating cytokine or said flavonoid and said compound effective to inhibit the production or release of intracellular hydrogen peroxide is performed simultaneously.
3. (Original) The method of Claim 1, wherein the administration of said compound effective to inhibit the production or release of intracellular hydrogen peroxide is performed within 24 hours of the administration of said NK cell activating cytokine or flavonoid.
4. (Original) The method of Claim 1, wherein said cytokine is administered in a dose of from about 1,000 to about 300,000 U/kg/day.
5. (Original) The method of Claim 1, wherein said flavonoid is administered in a dose of from about 1 to about 100,000 mg/day.
6. (Original) The method of Claim 1, wherein said histamine, other H<sub>2</sub>-receptor agonist or serotonin is administered in a dose of from about 0.1 to about 10 mg/day.
7. (Original) The method of Claim 1, wherein said NK cell activating cytokine or flavonoid and said compound effective to inhibit the production or release of intracellular hydrogen peroxide are administered parenterally to said subject.
8. (Currently amended) A method of inhibiting tumor growth in a subject suffering from neoplastic disease comprising:  
identifying a subject suffering from neoplastic disease;

**Appl. No.** : **10/076306**  
**Filed** : **February 12, 2002**

administering to said subject an effective NK-cell activating amount of an NK cell activating cytokine selected from the group consisting of IL-1, IL-12, IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$  or an NK cell activating flavonoid selected from the group consisting of flavone-8-acetic acid (FAA), xanthone-4-acetic acid (XAA), analogs of FAA, and methyl-substituted derivatives of FAA, ~~wherein said NK-cell activating cytokine is not IL-2 ; and~~

administering an effective amount of a hydrogen peroxide scavenger selected from the group consisting of catalase, superoxide dismutase, and glutathione peroxidase.

9. (Canceled)

10. (Canceled)

11. (Original) The method of Claim 8, wherein the administration of said NK cell activating cytokine or said flavonoid and said hydrogen peroxide scavenger is performed simultaneously.

12. (Original) The method of Claim 8, wherein the administration of said NK cell activating cytokine or said flavonoid and said hydrogen peroxide scavenger is performed within 24 hours.

13. (Original) The method of Claim 8, wherein said cytokine is administered in a dose of from about 1,000 to about 300,000 U/kg/day.

14. (Original) The method of Claim 8, wherein said flavonoid is administered in a dose of from about 1 to about 100,000 mg/day.

15. (Original) The method of Claim 8, wherein said hydrogen peroxide scavenger is administered in a dose of from about 0.1 to about 10 mg/day.

16. (Original) The method of Claim 8, wherein the administration of said NK cell activating cytokine or said flavonoid and said hydrogen peroxide scavenger is performed parenterally.